Interferon - Biosimilar Insight, 2022
This report can be delivered to the clients within 48-72 hours
DelveInsight’s, “Interferon– Biosimilar 2022,” report provides comprehensive insights about 10+ companies and 10+ marketed and pipeline drugs in Interferon Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Interferon: Overview
Interferons are a group of signaling proteins made and released by host cells in response to the presence of several viruses. In a typical scenario, a virus-infected cell will release interferons causing nearby cells to heighten their anti-viral defenses. Interferon is further categorized in its variants.
Interferon alfa-2b is an antiviral or antineoplastic drug. It is a recombinant form of the protein Interferon alpha-2 that was originally sequenced and produced recombinantly in E. coli in the laboratory of Charles Weissmann at the University of Zurich, in 1980.
Interferon beta-1a is a cytokine in the interferon family used to treat multiple sclerosis. It is produced by mammalian cells, while interferon beta-1b is produced in modified E. coli. Some claims have been made that Interferons produce about an 18–38% reduction in the rate of MS relapses.
Interferon Biosimilars: Drugs Chapters
This segment of the Interferon report encloses its detailed analysis of various drugs in different stages of clinical development, including marketed, phase III, II, I and preclinical. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Interferon Biosimilars: Marketed Drugs
Further product details are provided in the report……..
Interferon Biosimilars: Emerging Drugs
Further product details are provided in the report……..
Interferon: Therapeutic Assessment
This segment of the report provides insights about the different Interferon biosimilars segregated based on following parameters that define the scope of the report, such as:
Interferon: Pipeline Development Activities
The report provides insights into different therapeutic candidates in marketed, phase III, II, I and preclinical stage. It also analyses Interferon biosimilars drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Interferon biosimilar drugs.
Report Highlights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Interferon– Biosimilar 2022,” report provides comprehensive insights about 10+ companies and 10+ marketed and pipeline drugs in Interferon Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Interferon: Overview
Interferons are a group of signaling proteins made and released by host cells in response to the presence of several viruses. In a typical scenario, a virus-infected cell will release interferons causing nearby cells to heighten their anti-viral defenses. Interferon is further categorized in its variants.
Interferon alfa-2b is an antiviral or antineoplastic drug. It is a recombinant form of the protein Interferon alpha-2 that was originally sequenced and produced recombinantly in E. coli in the laboratory of Charles Weissmann at the University of Zurich, in 1980.
Interferon beta-1a is a cytokine in the interferon family used to treat multiple sclerosis. It is produced by mammalian cells, while interferon beta-1b is produced in modified E. coli. Some claims have been made that Interferons produce about an 18–38% reduction in the rate of MS relapses.
Interferon Biosimilars: Drugs Chapters
This segment of the Interferon report encloses its detailed analysis of various drugs in different stages of clinical development, including marketed, phase III, II, I and preclinical. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Interferon Biosimilars: Marketed Drugs
- Bioferon: Biosidus
Further product details are provided in the report……..
Interferon Biosimilars: Emerging Drugs
- Interferon beta-1b biosimilar: Harvest Moon Pharmaceuticals
Further product details are provided in the report……..
Interferon: Therapeutic Assessment
This segment of the report provides insights about the different Interferon biosimilars segregated based on following parameters that define the scope of the report, such as:
- Major Players in Interferon
- Phases
- Marketed stage products
- Late stage products (BLA Filed and Phase III)
- Mid-stage products (Phase II and
- Early-stage products (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Subcutaneous
- Intramuscular
- Molecule Type
- Monoclonal antibodies
- Peptide
- Protein
- Small molecule
- Product Type
Interferon: Pipeline Development Activities
The report provides insights into different therapeutic candidates in marketed, phase III, II, I and preclinical stage. It also analyses Interferon biosimilars drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Interferon biosimilar drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Interferon R&D. The therapies under development are focused on novel approaches to treat/improve Interferon.
- Interferon Biosimilar Pipeline Analysis
- Therapeutic Assessment
- Sales Assessment
- Unmet Needs
- Impact of Drugs
- Marketed Product profiles
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Sales Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Interferon Biosimilars?
- How many Interferon biosimilars are developed by each company?
- How many emerging biosimilars are in mid-stage, and late-stage?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Interferon biosimilars therapeutics?
- What are the clinical studies going on for Interferon biosimilars and their status?
- What are the key designations that have been granted to the emerging drugs?
- Zydus Cadila
- Reliance Life Sciences
- Profarma
- Harvest Moon Pharmaceuticals
- Dong-A ST
- CinnaGen
- BioPartners
- Biocad
- Amega Biotech
- MAB 2
- ReliBeta
- PF-08
- Interferon beta-1b biosimilar
- DA-3051
- Cinno Vex
- ReciGen
- Bioferon
- Inmutag
- Alpheon
- BCD-033
- Megavex
1. KEY INSIGHTS
2. INTERFERON BIOSIMILARS: SNAPSHOT
3. EXECUTIVE SUMMARY
3.1. Overview
3.2. The Basics of Biologics.
3.3. Biosimilars are not the Same as Generic Drugs
3.4. Economics of Biosimilars – the Promise of Lower Prices, but at What Cost?
3.5. What Patients Need to Know About Biosimilars
4. REGULATORY OUTLOOK FOR BIOSIMILARS
4.1. North America
4.1.1. US
4.1.2. Canada
4.2. Europe
4.3. Asia Pacific
4.3.1. China
4.3.2. India
4.3.3. Japan
4.3.4. South Korea
4.3.5. Australia
4.4. Rest Of The World
4.4.1. Brazil
4.4.2. Mexico
4.4.3. Argentina
4.4.4. Saudi Arabia
*More Countries would be added in the final report
5. INTERFERON (REFERENCE PRODUCT: AVONEX)
5.1. Drug Profile
5.2. Product Overview
5.3. Regulatory Approvals and Launch
5.4. Indications
5.5. Mechanism of Action
5.6. Dosage and Administration
5.7. Dosage and Strengths
5.8. Dose Modification
5.9. Route of Synthesis
5.10. Pharmacology
5.11. Pharmacodynamics
5.12. Pharmacokinetics
5.13. Adverse Reactions
5.14. Product Snapshot
5.15. Development Milestones
6. RESEARCH AND DEVELOPMENT
6.1. Clinical Trials Information
6.2. Safety and Efficacy
7. AVONEX BIOSIMILAR: EMERGING OPPORTUNITIES
*More variants of Interferon would be added in the final report
8. INTERFERON: BIOSIMILARS ASSESSMENT
8.1. Assessment by Product Type
8.2. Assessment by Route of Administration
8.3. Assessment by Molecule type
8.4. Sales Assessment
9. INTERFERON BIOSIMILARS PROFILES: BY COMPANY
9.1.1. Zydus Cadila
9.1.1.1. MAB 2: Zydus Cadila
9.1.1.1.1. Product Information
9.1.1.1.2. Research and Development
9.1.1.1.3. Other Development Activities
9.1.1.1.4. General Description Table
9.1.2. Profarma
9.1.2.1. PF-08: Profarma
9.1.2.1.1. Product Information
9.1.2.1.2. Research and Development
9.1.2.1.3. Other Development Activities
9.1.2.1.4. General Description Table
*More Companies and products would be added in the final report
10. INTERFERON BIOSIMILARS: COMPARATIVE LANDSCAPE: BY COMPANY
11. INTERFERON BIOSIMILARS: COMPETITIVE LANDSCAPE
11.1.1. Overview
11.1.2. Market Share Analysis
11.1.3. Competitive Scenario
11.1.3.1. Product Launches and approval
11.1.3.2. Partnerships, Collaborations and Agreements
11.1.3.3. Acquisitions
11.1.3.4. Expansions
11.1.3.5. Patent Expiration of Biologics
*More information would be added in the final report
12. MARKET DRIVERS
13. MARKET BARRIERS
14. SWOT ANALYSIS
15. APPENDIX
15.1. Research Methodology
15.1.1. Coverage
15.1.2. Secondary Research
16. BIBLIOGRAPHY
17. DELVEINSIGHT CAPABILITIES
18. DISCLAIMER
19. ABOUT DELVEINSIGHT
2. INTERFERON BIOSIMILARS: SNAPSHOT
3. EXECUTIVE SUMMARY
3.1. Overview
3.2. The Basics of Biologics.
3.3. Biosimilars are not the Same as Generic Drugs
3.4. Economics of Biosimilars – the Promise of Lower Prices, but at What Cost?
3.5. What Patients Need to Know About Biosimilars
4. REGULATORY OUTLOOK FOR BIOSIMILARS
4.1. North America
4.1.1. US
4.1.2. Canada
4.2. Europe
4.3. Asia Pacific
4.3.1. China
4.3.2. India
4.3.3. Japan
4.3.4. South Korea
4.3.5. Australia
4.4. Rest Of The World
4.4.1. Brazil
4.4.2. Mexico
4.4.3. Argentina
4.4.4. Saudi Arabia
*More Countries would be added in the final report
5. INTERFERON (REFERENCE PRODUCT: AVONEX)
5.1. Drug Profile
5.2. Product Overview
5.3. Regulatory Approvals and Launch
5.4. Indications
5.5. Mechanism of Action
5.6. Dosage and Administration
5.7. Dosage and Strengths
5.8. Dose Modification
5.9. Route of Synthesis
5.10. Pharmacology
5.11. Pharmacodynamics
5.12. Pharmacokinetics
5.13. Adverse Reactions
5.14. Product Snapshot
5.15. Development Milestones
6. RESEARCH AND DEVELOPMENT
6.1. Clinical Trials Information
6.2. Safety and Efficacy
7. AVONEX BIOSIMILAR: EMERGING OPPORTUNITIES
*More variants of Interferon would be added in the final report
8. INTERFERON: BIOSIMILARS ASSESSMENT
8.1. Assessment by Product Type
8.2. Assessment by Route of Administration
8.3. Assessment by Molecule type
8.4. Sales Assessment
9. INTERFERON BIOSIMILARS PROFILES: BY COMPANY
9.1.1. Zydus Cadila
9.1.1.1. MAB 2: Zydus Cadila
9.1.1.1.1. Product Information
9.1.1.1.2. Research and Development
9.1.1.1.3. Other Development Activities
9.1.1.1.4. General Description Table
9.1.2. Profarma
9.1.2.1. PF-08: Profarma
9.1.2.1.1. Product Information
9.1.2.1.2. Research and Development
9.1.2.1.3. Other Development Activities
9.1.2.1.4. General Description Table
*More Companies and products would be added in the final report
10. INTERFERON BIOSIMILARS: COMPARATIVE LANDSCAPE: BY COMPANY
11. INTERFERON BIOSIMILARS: COMPETITIVE LANDSCAPE
11.1.1. Overview
11.1.2. Market Share Analysis
11.1.3. Competitive Scenario
11.1.3.1. Product Launches and approval
11.1.3.2. Partnerships, Collaborations and Agreements
11.1.3.3. Acquisitions
11.1.3.4. Expansions
11.1.3.5. Patent Expiration of Biologics
*More information would be added in the final report
12. MARKET DRIVERS
13. MARKET BARRIERS
14. SWOT ANALYSIS
15. APPENDIX
15.1. Research Methodology
15.1.1. Coverage
15.1.2. Secondary Research
16. BIBLIOGRAPHY
17. DELVEINSIGHT CAPABILITIES
18. DISCLAIMER
19. ABOUT DELVEINSIGHT
